Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML).
Read the full article on WikipediaChronic lymphocytic leukaemia (CLL) Clinical criteria: Treatment Phase: Dose titration for relapsed/refractory disease The condition must have relapsed or be refractory to at least one prior therapy, AND The treatment must be the sole PBS-subsidised therapy for this condition, AND The treatment must only be prescribed for a patient with active disease in accordance with the International Workshop on CLL (iwCLL) guidance (latest version) in relation to when to prescribe drug treatment for this condition. Treatment criteria: Patient must not be undergoing retreatment with this drug where any of: (i) prior treatment of CLL/SLL with this same drug was unable to prevent disease progression; (ii) 24 months of PBS-subsidised treatment has been administered with this drug for this condition.
Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) Clinical criteria: Treatment Phase: Dose modification The treatment must be for dose titration purposes.
Acute Myeloid Leukaemia Clinical criteria: The condition must be previously untreated at the time of initiation with this drug (except for essential treatment with hydroxyurea or leukapheresis), AND Patient must not be considered eligible for standard intensive remission induction chemotherapy at the time of initiation with this drug, AND The treatment must be used in combination with azacitidine (refer to Product Information for timing of azacitidine and venetoclax doses), AND Patient must not have progressive disease while receiving PBS-subsidised treatment with this drug for this condition, AND The condition must not be acute promyelocytic leukaemia. Progressive disease monitoring via a complete blood count must be taken at the end of each cycle. If abnormal blood counts suggest the potential for relapsed AML, a bone marrow biopsy must be performed to confirm the absence of progressive disease for the patient to be eligible for further cycles.
“Venetoclax is a BH3-mimetic and was the first approved drug targeting protein-protein interactions. Venetoclax blocks the anti-apoptotic B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death of CLL cells. Overexpression of Bcl-2 in some lymphoid malignancies has been linked to increased resistance to chemotherapy.”
“~26 hours”
Working under the parallel aged-care framework? Aged-care equivalent →